Swiss HIV Cohort Study

Surial et al., Prise de poids après le passage de ténofovir disoproxil à ténofovir alafenamide

Prise de poids après le passage de ténofovir disoproxil à ténofovir alafenamide Le médicament ténofovir est un élément important des thérapies combinées du VIH en raison de son excellente efficacité et de sa tolérance. La forme Tenofovir disoproxil fumarat (TDF), autrefois largement utilisée, a été associée à une maladie rénale (appelée tubulopathie rénale proximale) et […]

Surial et al., Aumento di peso dopo il passaggio da tenofovir disoproxil a tenofovir alafenamide

Aumento di peso dopo il passaggio da tenofovir disoproxil a tenofoviralafenamide Il medicamento tenofovir è una componente importante nelle terapie combinate per l’HIV in considerazione della sua eccellente efficacia e tolleranza. La formulazione tenofovir disoproxil fumarato (TDF), in passato largamente utilizzata, è stata associata ad una malattia renale (denominata tubulopatia renale prossimale) e allo sviluppo […]

Surial et al., Gewichtszunahme nach Umstellung von Tenofovir disoproxil auf Tenofovir alafenamid

Gewichtszunahme nach Umstellung von Tenofovir disoproxil (TDF) auf Tenofovir alafenamid (TAF) Das Medikament Tenofovir ist aufgrund der ausgezeichneten Wirksamkeit und Verträglichkeit ein wichtiger Bestandteil der HIV Kombinationstherapien. Die früher weit verbreitete Form Tenofovir disoproxil fumarat (TDF) wurde mit einer Nierenerkrankung (der sogenannten proximalen renalen Tubulopathie) sowie der Entwicklung von Knochenschwund in Verbindung gebracht. Die neuere […]

Chammartin et al., non-AIDS-defining and AIDS-defining cancer and timing of ART initiation

Risk for non–AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy.    Annals of Internal Medicine Chammartin et al. aimed to assess the impact of deferred and immediate start of antiretroviral therapy (ART) on the development of non-AIDS and AIDS-defining cancer. Authors estimated the occurrence of cancer among participants from the D:A:D […]

funding of the SHCS by the SNSF from 2021 to 2024 – thanks to all

Dear all, We are very pleased to inform you that the SHCS will be funded with CHF 8,75 Mio from the Swiss National Science Foundation (SNSF) for the next 3,5 years (CHF 2,5 Mio/year). The reason we are still supported in these fast-moving times after 33 years is excellence in clinical care and outstanding research. […]

Surial and Mugglin et al., Metabolic changes after replacing TDF with TAF

Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV.    Annals of Internal Medicine. Surial and Mugglin et al. evaluated the impact of switching from Tenofovir disoproxil fumarate (TDF) to Tenofovir alafenamide (TAF) on weight, the development of obesity and other metabolic outcomes among participants on […]

Stader et al., Effect of ageing on antiretroviral drug pharmacokinetics

Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation.    British Journal of Clinical Pharmacology Stader et al. aimed to investigate age-related pharmacokinetic changes of HIV drugs by using a previously developed and verified physiologically based pharmacokinetic (PBPK) framework in combination with clinically observed data sampled as part of […]

Roen et al., Health care index predicts TB-HIV mortality

A new health care index predicts short term mortality for TB and HIV co-infected people.    International Journal of Tuberculosis and Lung Roen et al. aimed to re-evaluate a previously generated health care index (HCI) in a prospective cohort of tuberculosis (TB-) HIV co-infected individuals and to asses if additional factors, which parallel recent changes in […]

Thorball et al., Host genomics of the HIV-1 reservoir

Host genomics of the HIV-1 reservoir size and its decay rate during suppressive antiretroviral treatment.    JAIDS Thorball et al. aimed to assess host genetic factors associated with the HIV-1 reservoir size and its long-term dynamics in a cohort of 797 HIV-1 positive individuals on suppressive antiretroviral therapy (ART) for at least 5 years. The […]

Neesgaard et al., Outcomes of integrase inhibitors treatment

Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium.   PLoS One Neesgaard et al. for The RESPOND study group aimed to compare virologic and immunologic outcomes of integrase inhibitor (INSTI)-containing, contemporary boosted protease inhibitor (PI/b)-containing and non-nucleotide reverse transcriptase inhibitor (NNRTI)-containing regimens in a real-life setting. Virologic […]